Valuation: Jupiter Neurosciences, Inc.

Market Cap 2.7M 2.42M 2.23M 2.02M 3.77M 257M 3.84M 26.55M 10.66M 135M 10.14M 9.93M 426M P/E 2024
-126x
P/E 2025 -4.08x
Enterprise Value 4.23M 3.79M 3.49M 3.16M 5.91M 402M 6.02M 41.58M 16.69M 211M 15.89M 15.55M 667M EV / Sales 2024
-
EV / Sales 2025 1,681x
Free-Float
70.04%
Yield 2024 *
-
Yield 2025 -
1 day-13.50%
1 week-31.21%
1 month-15.98%
3 months-69.63%
6 months-92.79%
Current year-97.32%
1 week 2.05
Extreme 2.05
3.01
1 month 2.05
Extreme 2.05
3.5
Current year 2.05
Extreme 2.05
81.75
1 year 2.05
Extreme 2.05
105
3 years 2.05
Extreme 2.05
1,463.25
5 years 2.05
Extreme 2.05
1,463.25
10 years 2.05
Extreme 2.05
1,463.25
Manager TitleAgeSince
Chief Administrative Officer 34 2015-12-31
Chief Tech/Sci/R&D Officer 71 2015-12-31
Chief Executive Officer 74 2015-12-31
Director TitleAgeSince
Chairman 74 2015-12-31
Director/Board Member 71 2015-12-31
Director/Board Member 48 2017-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/31/26 Free

Director

472,222 0.9792%
6/29/26 Free

Director

536,428 1.1124%
6/2/26 Free

Director

100,000 0.2756%
Change 5-day change 1-year change 3-year change Capi.($)
-13.50%-31.21%-98.09% - 2.7M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -1.04%+3.66%+33.01%+194.99% 39.43B
Weighted average by Cap. +0.18%+5.44%+47.99%+176.67%

Financials

2024 2025
Net sales - 21.8K 19.52K 17.96K 16.27K 30.41K 2.07M 30.98K 214K 85.96K 1.09M 81.8K 80.06K 3.43M
Net income -2.44M -2.18M -2.01M -1.82M -3.4M -232M -3.47M -23.97M -9.62M -122M -9.16M -8.96M -384M -8.64M -7.74M -7.12M -6.45M -12.06M -821M -12.29M -84.93M -34.09M -432M -32.44M -31.75M -1.36B
Net Debt -3.55M -3.18M -2.93M -2.65M -4.96M -337M -5.05M -34.89M -14.01M -177M -13.33M -13.05M -559M 1.53M 1.37M 1.26M 1.14M 2.13M 145M 2.17M 15.03M 6.03M 76.42M 5.74M 5.62M 241M
Projected Income Statement - Annual - Jupiter Neurosciences, Inc.
Logo Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer market with its Nugevia product line. The Company's pharmaceutical product pipeline is built around its proprietary platform product, JOTROL, an enhanced oral formulation of resveratrol. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Its segments include premium nutritional supplements, and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. The Company's Nugevia product line supplements space, supporting mental clarity, skin health, and mitochondrial function. It is also focused on a Phase IIa clinical study in Parkinson's disease. It also has rights in ALA-002.
Employees
-
Date Price Change Volume
26-10-30 US$2.050 -13.50% 18,031
26-10-29 US$2.370 -5.20% 7,413
26-10-28 US$2.500 -5.30% 29,724
26-10-27 US$2.640 -7.69% 41,719
26-10-26 US$2.860 -4.03% 12,902

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Jupiter Neurosciences, Inc.
  1. Stock Market
  2. Stocks
  3. JUNS Stock